Get started
Author

Andrew Walding

Observed names: A Walding, A. Walding, Andrew Stephen Walding, Walding, Andrew
OpenAlex ID: A5082546105
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
2016 · M.-J. Ahn, J. Yang, et al. · Journal of Thoracic Oncology · 234
PDF
Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA
2021 · Masahiro Tsuboi, Walter Weder, et al. · Future Oncology · 192
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
2021 · Ying Cheng, Yong He, et al. · Targeted Oncology · 170
PDF
Human peripheral blood mononuclear cells express GABAA receptor subunits
2005 · Sabina Alam, David L. Laughton, et al. · Molecular Immunology · 160
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
2018 · Yuichiro Ohe, Fumio Imamura, et al. · Japanese Journal of Clinical Oncology · 152
PDF
Monomethylfumarate affects polarization of monocyte‐derived dendritic cells resulting in down‐regulated Th1 lymphocyte responses
2004 · Nicolle H. R. Litjens, Mirjam Rademaker, et al. · European Journal of Immunology · 106
Cardiac Safety of Osimertinib: A Review of Data
2020 · Michael S. Ewer, Sri Harsha Tekumalla, et al. · Journal of Clinical Oncology · 91
PDF
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
2022 · Myung-Ju Ahn, Byoung Chul Cho, et al. · Journal of Thoracic Oncology · 81
PDF
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
2019 · Natasha B. Leighl, Nina Karaseva, et al. · European Journal of Cancer · 70
PDF
Activation of E-prostanoid4and E-prostanoid2receptors inhibits TNF-α release from human alveolar macrophages
2007 · M. J. Ratcliffe, A. Walding, et al. · European Respiratory Journal · 59
PDF
Large‐scale isolation of human skeletal muscle satellite cells from post‐mortem tissue and development of quantitative assays to evaluate modulators of myogenesis
2013 · Ian C. Scott, Wendy Tomlinson, et al. · Journal of Cachexia Sarcopenia and Muscle · 37
PDF
Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists
2010 · Christopher A. Luckhurst, Linda A. Stein, et al. · Bioorganic & Medicinal Chemistry Letters · 33
Differential gene expression analysis in human monocyte-derived macrophages: Impact of cigarette smoke on host defence
2009 · Ian Doyle, Marianne Ratcliffe, et al. · Molecular Immunology · 33
SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.
2021 · Seock-Ah Im, Erika P. Hamilton, et al. · Journal of Clinical Oncology · 30
Correlation of gene and mediator expression with clinical endpoints in an acute interleukin-1β-driven model of joint pathology
2008 · I. Scott, A. Midha, et al. · Osteoarthritis and Cartilage · 26
Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer
2018 · Martin Sebastian, Anna Rydén, et al. · Lung Cancer · 15
PDF
P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
2021 · M. Tsuboi, W. Weder, et al. · Journal of Thoracic Oncology · 14
PDF
Abstract OT2-11-05: SERENA-6: A Phase III study to assess the efficacy and safety of AZD9833 (camizestrant) compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1m who have not experienced disease progression on first-line therapy
2022 · François-Clément Bidard, Kevin Kalinsky, et al. · Cancer Research · 13
Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy
2017 · Anna Rydén, Fiona Blackhall, et al. · Patient · 13
CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer
2025 · Erika P. Hamilton, Sibylle Loibl, et al. · Future Oncology · 12
Abstract OT2-11-06: SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease
2022 · Fabrice André, Seock-Ah Im, et al. · Cancer Research · 11
Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARδ agonists
2010 · Christopher A. Luckhurst, Marianne Ratcliffe, et al. · Bioorganic & Medicinal Chemistry Letters · 11
Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions
2022 · Andrew Walding, Konstantina Skaltsa, et al. · Quality of Life Research · 7
PDF
139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)
2018 · N. Leighl, N. Karaseva, et al. · Journal of Thoracic Oncology · 7
PDF
How patients being treated for non-small cell lung cancer value treatment benefit despite side effects
2021 · Mona L. Martin, Julia Correll, et al. · Quality of Life Research · 6
PDF
Works count: 42
Citation count: 1,598
H-index: 15
I10-index: 22
Year
Topic
Type